NVO
$38.43
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Recent News
Health Care Roundup: Market Talk
1515 ET – For obesity-drug makers, success will be defined by price rather than product differentiation, HSBC analysts say. Pricing competition is set to heat up between Eli Lilly and Novo Nordisk, the analysts say. Lilly’s current guidance — which is more optimistic than Novo Nordisk’s — implies it will get a surge in GLP-1 demand when it cuts prices.
HSBC Downgrades Eli Lilly, Cuts PT to $850, Flags Obesity Market Risks
Analysts say pricing pressure and competition could limit market growth to $80B--$120B, below consensus expectations above $150B.
Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
Novo Nordisk (CPSE:NOVO B) has entered a partnership with Hims & Hers to provide access to its FDA approved GLP-1 obesity and diabetes drugs, Ozempic and Wegovy, through telehealth channels. The agreement resolves a public legal dispute between the two companies and could influence how patients in the United States access branded GLP-1 treatments. The announcement comes at a time of increasing competition and the rise of copycat medications in the obesity treatment space. For investors...
Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up.
Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.
Why Eli Lilly Stock Just Dropped
Eli Lilly's stock price is based on growth rates that might fall short.